ORLANDO, Fla.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today presented positive results from a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway. Study results suggest that ACE-041 monotherapy may prevent tumor growth by inhibiting ALK1-mediated angiogenesis. Findings were presented during the annual meeting of the American Association of Cancer Research (AACR) by Johanna Bendell, M.D., from the Sarah Cannon Research Institute.
